ACRS (Aclaris Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

ACRS (Aclaris Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

Mkt Cap$435M

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Revenue (TTM)$8M

Net Income (TTM)-$65M

EPS (TTM)-$0.53

Free Cash Flow (TTM)-$47M

Gross Margin73.3%

Op. Margin-975.9%

Net Margin-829.6%

FCF Margin-602.6%

P/S Ratio (TTM)55.6x

P/E Ratio (TTM)—

YoY Rev Growth-58.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$3M	$659K	-$30M
Q2 23	$2M	$277K	-$32M
Q3 23	$9M	$1M	-$32M
Q4 23	$18M	$11M	-$4M
Q1 24	$2M	$558K	-$19M
Q2 24	$3M	$857K	-$13M
Q3 24	$4M	$2M	-$10M
Q4 24	$9M	-$90K	-$100M
Q1 25	$1M	$949K	-$18M
Q2 25	$2M	-$73K	-$18M
Q3 25	$3M	$3M	-$17M
Q4 25	$1M	$2M	-$23M

Valuation

Quarter	P/S	P/E
Q1 23	14.1x	—
Q2 23	13.9x	—
Q3 23	20.3x	—
Q4 23	13.9x	—
Q1 24	14.0x	—
Q2 24	13.6x	—
Q3 24	16.1x	—
Q4 24	23.2x	—
Q1 25	24.5x	—
Q2 25	25.9x	—
Q3 25	27.6x	—
Q4 25	55.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$26M	-$27M
Q2 23	-$21M	-$21M
Q3 23	-$25M	-$25M
Q4 23	-$7M	-$7M
Q1 24	-$21M	-$21M
Q2 24	-$12M	-$12M
Q3 24	$22M	$22M
Q4 24	-$9M	-$45M
Q1 25	-$13M	-$13M
Q2 25	-$10M	-$10M
Q3 25	-$11M	-$11M
Q4 25	-$13M	-$13M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$553K
Q2 23	$231K
Q3 23	$84K
Q4 23	$441K
Q1 24	$135K
Q2 24	$14K
Q3 24	$0
Q4 24	$36M
Q1 25	$43K
Q2 25	$21K
Q3 25	$23K
Q4 25	$44K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+74.0%	+59.4%
Q2 23	+22.3%	+49.6%
Q3 23	-51.2%	+2.4%
Q4 23	+126.6%	-41.3%
Q1 24	-5.1%	-34.3%
Q2 24	+48.0%	-53.6%
Q3 24	-53.2%	-63.7%
Q4 24	-47.6%	+403.7%
Q1 25	-39.3%	-8.4%
Q2 25	-35.8%	+29.2%
Q3 25	-24.1%	+38.0%
Q4 25	-85.9%	-77.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$7M	269.2%
Q2 23	$7M	349.0%
Q3 23	$6M	64.1%
Q4 23	$1M	7.2%
Q1 24	$2M	87.1%
Q2 24	$3M	105.0%
Q3 24	$0	0.0%
Q4 24	$3M	31.0%
Q1 25	$4M	243.0%
Q2 25	$3M	172.4%
Q3 25	$0	0.0%
Q4 25	$3M	225.9%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$23M	$9M
Q2 23	$25M	$7M
Q3 23	$24M	$7M
Q4 23	$27M	$8M
Q1 24	$10M	$7M
Q2 24	$9M	$5M
Q3 24	$6M	$6M
Q4 24	$9M	$5M
Q1 25	$12M	$6M
Q2 25	$11M	$5M
Q3 25	$13M	$5M
Q4 25	$17M	$6M

Revenue Segments

Quarter	Contract research	License and Service
Q1 23	$889K	$2M
Q2 23	$875K	$994K
Q3 23	$705K	$9M
Q1 24	$657K	$2M
Q2 24	$625K	$2M
Q3 24	$645K	$4M
Q1 25	$445K	$1M
Q2 25	$442K	$1M
Q3 25	$485K	$3M
Q4 25	$500K	$795K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$45M	$126M	$171M
Q2 23	$31M	$89M	$120M
Q3 23	$39M	$64M	$103M
Q4 23	$40M	$79M	$119M
Q1 24	$36M	$92M	$128M
Q2 24	$23M	$88M	$111M
Q3 24	$48M	$80M	$128M
Q4 24	$25M	$89M	$114M
Q1 25	$30M	$75M	$105M
Q2 25	$25M	$74M	$100M
Q3 25	$25M	$71M	$96M
Q4 25	$20M	$71M	$91M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	67M	+0.3%
Q2 23	71M	+5.6%
Q3 23	71M	+0.2%
Q4 23	71M	+0.1%
Q1 24	71M	+0.3%
Q2 24	71M	+0.3%
Q3 24	71M	+0.1%
Q4 24	95M	+33.5%
Q1 25	122M	+28.4%
Q2 25	123M	+0.2%
Q3 25	123M	+0.0%
Q4 25	123M	+0.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	$0	18
FY 16	$0	31
FY 17	$18K	96
FY 18	$60K	169
FY 19	$55K	77
FY 20	$108K	60
FY 21	$88K	77
FY 22	$283K	105
FY 23	$343K	91
FY 24	$293K	64
FY 25	$107K	73